These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25941009)

  • 1. Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties.
    Huang G; Nimczick M; Decker M
    Arch Pharm (Weinheim); 2015 Aug; 348(8):531-40. PubMed ID: 25941009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design of dualsteric GPCR ligands: quests and promise.
    Mohr K; Tränkle C; Kostenis E; Barocelli E; De Amici M; Holzgrabe U
    Br J Pharmacol; 2010 Mar; 159(5):997-1008. PubMed ID: 20136835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.
    Mohr K; Schmitz J; Schrage R; Tränkle C; Holzgrabe U
    Angew Chem Int Ed Engl; 2013 Jan; 52(2):508-16. PubMed ID: 23225228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology.
    Leach K; Sexton PM; Christopoulos A
    Trends Pharmacol Sci; 2007 Aug; 28(8):382-9. PubMed ID: 17629965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.
    Valant C; Sexton PM; Christopoulos A
    Mol Interv; 2009 Jun; 9(3):125-35. PubMed ID: 19592673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities.
    De Amici M; Dallanoce C; Holzgrabe U; Tränkle C; Mohr K
    Med Res Rev; 2010 May; 30(3):463-549. PubMed ID: 19557759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?
    Michino M; Beuming T; Donthamsetti P; Newman AH; Javitch JA; Shi L
    Pharmacol Rev; 2015; 67(1):198-213. PubMed ID: 25527701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.
    Lu S; Zhang J
    J Med Chem; 2019 Jan; 62(1):24-45. PubMed ID: 29457894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bridging the gap: bitopic ligands of G-protein-coupled receptors.
    Lane JR; Sexton PM; Christopoulos A
    Trends Pharmacol Sci; 2013 Jan; 34(1):59-66. PubMed ID: 23177916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity.
    Antony J; Kellershohn K; Mohr-Andrä M; Kebig A; Prilla S; Muth M; Heller E; Disingrini T; Dallanoce C; Bertoni S; Schrobang J; Tränkle C; Kostenis E; Christopoulos A; Höltje HD; Barocelli E; De Amici M; Holzgrabe U; Mohr K
    FASEB J; 2009 Feb; 23(2):442-50. PubMed ID: 18842964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance.
    Bosier B; Hermans E
    Trends Pharmacol Sci; 2007 Aug; 28(8):438-46. PubMed ID: 17629964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities.
    Seifert R; Dove S
    Mol Pharmacol; 2009 Jan; 75(1):13-8. PubMed ID: 19001067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating structural and mutagenesis data to elucidate GPCR ligand binding.
    Munk C; Harpsøe K; Hauser AS; Isberg V; Gloriam DE
    Curr Opin Pharmacol; 2016 Oct; 30():51-58. PubMed ID: 27475047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structures of G protein-coupled receptors reveal new opportunities for drug discovery.
    Cooke RM; Brown AJ; Marshall FH; Mason JS
    Drug Discov Today; 2015 Nov; 20(11):1355-64. PubMed ID: 26303408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
    Heilker R; Wolff M; Tautermann CS; Bieler M
    Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When simple agonism is not enough: emerging modalities of GPCR ligands.
    Smith NJ; Bennett KA; Milligan G
    Mol Cell Endocrinol; 2011 Jan; 331(2):241-7. PubMed ID: 20654693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I want a new drug: G-protein-coupled receptors in drug development.
    Schlyer S; Horuk R
    Drug Discov Today; 2006 Jun; 11(11-12):481-93. PubMed ID: 16713899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
    Huber T; Menon S; Sakmar TP
    Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging opportunities for allosteric modulation of G-protein coupled receptors.
    Wang CI; Lewis RJ
    Biochem Pharmacol; 2013 Jan; 85(2):153-62. PubMed ID: 22975406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric modulation of G protein-coupled receptors.
    May LT; Leach K; Sexton PM; Christopoulos A
    Annu Rev Pharmacol Toxicol; 2007; 47():1-51. PubMed ID: 17009927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.